Gary O’neill
Senior Vice President, Research
Healthcare
NaturEscape Inc
Austria
Biography
Dr. O’Neill currently serves as the Senior Vice President of Research at Abide Therapeutics after joining the company in October of 2013 as Vice President of Biology. He has more than 25 years of experience advancing therapeutic candidates from target drug discovery to clinical trials. Prior to Abide, Dr. O’Neill worked at Merck Research Laboratories in Boston, where he held the roles of Discovery Site Head and Vice President. There he was responsible for Merck’s preclinical drug discovery programs in respiratory, immunology and oncology and was accountable for the business operations of In Vitro Pharmacology and In Vivo Pharmacology. Prior to his role at Merck-Boston, Gary was the Head of Biology at Merck Frosst Basic Research Laboratories, Montreal, Canada. There, he led a research team that advanced a number of small molecule candidates, focused primarily on the treatment of asthma, COPD, inflammation, pain, diabetes, obesity, and cardiovascular indications, from the lab into the clinic.
Research Interest
Dr. O’Neill currently serves as the Senior Vice President of Research at Abide Therapeutics after joining the company in October of 2013 as Vice President of Biology. He has more than 25 years of experience advancing therapeutic candidates from target drug discovery to clinical trials. Prior to Abide, Dr. O’Neill worked at Merck Research Laboratories in Boston, where he held the roles of Discovery Site Head and Vice President. There he was responsible for Merck’s preclinical drug discovery programs in respiratory, immunology and oncology and was accountable for the business operations of In Vitro Pharmacology and In Vivo Pharmacology. Prior to his role at Merck-Boston, Gary was the Head of Biology at Merck Frosst Basic Research Laboratories, Montreal, Canada. There, he led a research team that advanced a number of small molecule candidates, focused primarily on the treatment of asthma, COPD, inflammation, pain, diabetes, obesity, and cardiovascular indications, from the lab into the clinic.
